AIM ImmunoTech Inc. 8K

AIM ImmunoTech announced Q2 2026 results, stronger liquidity, completion of a key Phase 2 pancreatic cancer trial stage, Phase 3 planning, and new government-focused Ebola initiatives while regaining NYSE American compliance.

AIM ImmunoTech Inc. reported its financial results for the quarter ended June 30, 2026, highlighting a significantly strengthened cash position, completion of patient enrollment and Ampligen dosing in its Phase 2 DURIPANC metastatic pancreatic cancer trial, engagement of Thermo Fisher Scientific’s PPD clinical research business to support design of a planned pivotal Phase 3 trial, ongoing encouraging clinical observations from Erasmus MC Cancer Institute, regained compliance with NYSE American listing standards, and plans to pursue government-funded initiatives to evaluate Ampligen’s antiviral potential against Ebola, with key DURIPANC clinical benefit data expected in Q1 2027 and overall survival data in Q3 2027.

Filing Facts

CIK

946644

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-036753

Alert Tier

6